Aveanna Healthcare's Private Equity Owners Are Selling Down Again

Aveanna Healthcare stock dropped 9.2% in after-hours trading Thursday after the company announced a secondary offering of 15 million shares. That was the bad news for shareholders. The weirder part: the company isn't selling any of those shares and won't receive any of the proceeds.

Again.

The basic point is that this is a private equity firm liquidating its position in a business it helped create, using the public markets as the exit door. The company gets a press release and a stock decline. J.H. Whitney gets cash. The rest of us have to figure out whether this is a normal feature of PE-owned companies or a reason to be nervous.

What a secondary offering actually is

A secondary offering by "selling stockholders" is the securities-law name for insiders cashing out. The company files the paperwork — because the shares are registered with the SEC — but the money goes straight from the new buyer to the old holder. It's not dilutive in the sense that the company isn't creating new shares to fund its own operations. But it is dilutive to the narrative, because it tells the market that the people who were supposed to be most committed to the stock are no longer interested in holding it.

In this case, the selling stockholders are affiliates of J.H. Whitney Equity Partners VII, LLC, along with certain current and former directors and officers. RBC Capital Markets is the sole book-runner. Whitney also granted the underwriter a 30-day option to buy up to an additional 2.25 million shares, so the offering could reach 17.25 million shares, or roughly 8% of the roughly 215 million shares outstanding.

If you think 15 million shares sounds like a lot, it is. At a current price around $13, that's about $200 million worth of stock changing hands in a single week.

The repetition is the signal

This isn't the first time Whitney has done this. In October 2025, just 10 months ago, Whitney-affiliated holders sold 10 million shares in a secondary offering at $9.00 per share, with Jefferies and J.P. Morgan as lead book-runners. The company, again, received nothing.

Two large secondary offerings in 10 months, both by the same PE firm, both at increasing prices, both bringing zero capital to the company. That is not the profile of an investor who is doubling down. That is the profile of an investor who is methodically working its way out.

The timeline makes the mechanics even clearer. Whitney and Bain Capital co-created Aveanna in 2017 by merging two of their portfolio companies — Epic Health Services and PSA Healthcare — into a single home health platform. They took it public in April 2021 at $12 per share. The stock fell hard over the next few years, dropping to around $5.47 by March 2025. Then, as the company's operational metrics improved, the stock recovered to roughly $13, up about 61% year-to-date.

Whitney's first secondary at $9 in October 2025 was already a recovery play. This second one at roughly $13 is a cash-out play.

Who still owns the thing

As of June 30, 2026, J.H. Whitney VII, L.P. alone held about 10.1 million shares. But Whitney has multiple affiliated entities — PSA Healthcare Investment Holding LLC held another 15.5 million shares, with smaller affiliated entities holding a few more million on top of that. Bain Capital, the co-owner, held about 81.6 million shares. Together, under a stockholders' agreement that coordinates voting and share transfers, the Whitney-Bain group controlled roughly 110.7 million shares, or about 51% of the company.

After the October 2025 secondary and now this August one, Whitney's aggregate position has been cut by at least 25 million shares. Bain has been quiet on the selling side so far, but the stockholders' agreement that ties their hands together on voting also coordinates transfers. If Whitney is the lead exit driver and Bain goes along with the program, the PE firms could be substantially reducing their stake over the next 12 months.

The company that's left behind

Here's the part that makes this structurally interesting rather than just a routine PE exit. Aveanna is carrying roughly $1.48 billion in debt against a business that was technically insolvent — with negative shareholder equity — just a year ago. The debt-to-equity ratio sits at 6.62, which looks manageable until you remember that the equity base was negative, which means the ratio itself is a bit of a fiction. Over 60% of the company's total assets are goodwill, an intangible that can be written down when things go wrong.

The operations have improved. Q1 2026 revenue jumped 15.9% year-over-year to $648 million, with net income climbing from $5.2 million to $41.7 million. Adjusted EBITDA grew 25.2% to $84.4 million. The company raised its full-year revenue and EBITDA guidance. The management team has done real work here.

But none of that benefits from this offering. The company isn't getting a dime to pay down debt, fund acquisitions, or build capacity. The PE firm that created the leverage and still controls half the company is using the operational recovery as a reason to sell.

This is the classic private equity dynamic, compressed into one transaction: the PE firm built the platform, loaded it with debt, improved the operations, rode the stock higher, and is now selling its stake while the debt stays on the company's balance sheet. The people who put up the debt capital — the lenders — keep carrying the risk. The equity sellers get paid.

What the directors and officers piece means

The offering includes not just Whitney but also "certain current and former directors and officers." That's a separate incentive signal. When insiders are selling alongside the PE firm in a secondary offering, it doesn't necessarily mean the business is broken. But it does mean the people closest to the operation are participating in the same exit rhythm as the financial sponsor.

The prospectus supplement filed with the SEC will reveal exactly which directors and officers are selling and what portion of their holdings they're offloading. That detail matters — a director selling 100% of their stake is a different story than one selling 5%. But the mere fact that they're on the same deal sheet as Whitney tells you where the capital flow is going.

The simplest model

Here's how to think about this as an investor in the stock:

Aveanna is a roughly $2.8 billion company by market cap, carrying $1.48 billion in debt, generating roughly $330 million of annual EBITDA, growing revenue at about 16%, and controlled by two PE firms that together own about half the shares and have been selling down for 10 months.

The sellers have a different time horizon than the market. Whitney needs to harvest its investment while the stock is still on a good run. The market needs the company to keep delivering earnings growth that justifies the leverage. These aren't contradictory incentives — but they're not aligned either.

The company gets nothing from this sale. The stock takes a hit. And the PE firm that created the whole thing walks away with a few hundred million dollars more than it had last week. That's not a scandal. It's just how the machine works.